drugset

drugset / Trial / NCT06565689

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

NCT06565689 ↗

Phase 1 Recruiting 48 enrolled Excyte Biopharma Ltd

NaSequentialOpen-labelTreatment

Summary

This study aims to provide a basis for further clinical development of YK012.

Timeline

Start: 2023-05-09
Primary completion: 2028-12
Completion: 2028-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	YK012	Unknown	—	Intravenous

Indications